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TO THE EDITOR
Cumulative high-dose psoralen plus UVA
(PUVA) exposure variantly increases the
risk of skin cancer (especially nonmelano-
ma types). For example, its influence on
squamous cell carcinoma risk is enormous
(up to 250-fold) (Nijsten and Stern, 2003)
but remarkably weaker on basal cell
carcinoma (BCC) risk, particularly after
adjustment for other risk factors and sun
exposure (Stern et al., 1998; Nijsten and
Stern, 2003). Despite the clear link
between PUVA and skin cancer and a
roster of suspected pathogenic mecha-
nisms (for example, tumor initiation,
tumor promotion, local and systemic
immunosuppression, and direct stimula-
tion by oncogenic human papillomavirus)
(Wolf et al., 2004a), the exact mechanisms
of human PUVA-associated skin cancer
remain unknown.
Previously, we reported that the p53
mutations in a sample of 13 PUVA-
associated BCCs were most commonly
UV fingerprints (that is, C-T or CC-TT
transitions at dipyrimidine sites) and
less frequently potential PUVA finger-
prints at psoralen crosslinking sites (that
is, 50TpA or 50TpG sequences) (Seidl
et al., 2001). Half of those tumors,
however, contained no p53 mutations
at all, suggesting that other genes (for
example, the patched (PTCH) gene)
may have suffered PUVA damage.
Originally identified as the cause of
Gorlin’s syndrome (Hahn et al., 1996a;
Johnson et al., 1996), the PTCH gene
has since been found to be lost or
mutated in more than the half of
sporadic BCCs (Hahn et al., 1996b;
Unden et al., 1996; Xie et al., 1997;
Aszterbaum et al., 1998). More re-
cently, we detected PTCH gene muta-
tions in almost half (48% (29/60)) of a
sampling of BCCs obtained from the
general population (Heitzer et al.,
2007). This led us to examine the
potential role of PTCH gene mutation
in the molecular carcinogenesis of
PUVA-associated BCCs.
In brief, we analyzed the PTCH gene
in paraffin-embedded tumor specimens
from 8 of the 13 previously analyzed
PUVA-associated BCCs mentioned
above (Seidl et al., 2001).
Tissue sections were manually macro-
dissected (i) to eliminate nontumor cells
in tumor samples and (ii) to obtain
tumor-adjacent normal tissue from each
sample for control purposes. DNA from
PTCH gene exons 2–23 and adjacent
introns was amplified by PCR and
sequenced as previously described
(Heitzer et al., 2007). The study was
conducted according to the Declaration
of Helsinki Principles. At the time when
the study was performed, institutional
approval was not necessary for it,
according to Austrian laws and regula-
tions. Those patients who were still
alive gave their informed consent to
DNA analysis of the tumor samples.
Of the 8 BCCs analyzed, 5 (63%)
contained a total of 19 mutations (that
is, 9 missense, 1 nonsense, 7 silent
exonic, and 2 intronic mutations)
(Table 1). Four of those 5 BCCs had
multiple mutations. Of the 19 mutations,Abbreviations: BCC, basal cell carcinoma; PTCH, patched; PUVA, psoralen plus UVA
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17 (89%) occurred at dipyrimidine sites,
and 15 (79%) were C-T transitions.
Eleven mutations (58%) unambiguously
bore the UV fingerprint. Three mutations
(16%) that occurred at a 50TpG site
(tumor C1, codon 72) or 50TpT site
(tumor A3, codon 388 and tumor C1,
codon 83) unambiguously bore the
PUVA fingerprint, and one (5%) was of
other type, according to our previous
definition (Wolf et al., 2004b). The
remaining four mutations (21%) (tumor
A1, codon 289; tumor A2, codon 415;
tumor B2, codon 256; and tumor C1,
codon 514) were of uncertain (UV or
PUVA) origin, having occurred at a
dipyrimidine opposite a possible psora-
len-binding site (50TpG). Comparison of
DNA from tumor and adjacent normal
tissue samples revealed that every spe-
cific mutation, whether silent or not,
occurred only in tumor tissue, thus
indicating that each mutation was so-
matic. Three mutations (tumor A1, co-
don 289; tumor A3, codon 388; and
tumor B2, codon 293) in our study
population occurred at PTCH mutation
sites already entered in the
PTCH data bank (http://www.cybergene.
se/cgi-bin/w3-msql/ptchbase/index.html)
but exhibited base changes different to
those previously entered for the applicable
mutation sites. The other detected muta-
tions in our study were novel. Consistent
with previous work regarding BCC, most
(6 of 10) of the exonic nonsense or
missense PTCH mutations in our study
population were clustered in the extra-
cellular loop (four mutations) or sterol-
sensing domain (two mutations) (data not
shown), regions shown to be functionally
important in several previous studies
(Heitzer et al., 2007, and references cited
therein). In addition, in tumor and normal
tissue we detected a total of seven different
polymorphisms (IVS11-51G/C, 1665T/C,
1686C/T, IVS15þ 9G/C, IVS16-80G/C,
IVS17þ 21G/A, and 3944C/T or its
Table 1. PTCH mutations in PUVA-associated BCCs
Tumor suppressor gene
PTCH p531
Tumor2
Mutation
status
Exonic/intronic
position Codon
Codon and
flanking
sequence3
Base
change
Amino-acid
change
Strand containing
affected
pyrimidine4
Mutation
type5
Mutation
status
A1 Yes 6 289 tCATg C-T His-Tyr T UV/PUVA Yes
10 461 gGACt C-T None T UV
10 471 gCTGg C-T None T UV
23 1,344 gGGCc C-T Ala-Thr NT UV
A2 Yes 9 415 cTCCa C-T None T UV/PUVA Yes
A3 Yes 2 131 cTTCc C-T Glu-Lys NT UV Yes
8 388 cGTTc T-C Asn-Asp NT PUVA
19 1,099 tCACg C-T None T Other
23 1,423 cCCTc C-T None NT UV
B1 No No
B2 Yes 2 100 aCTTg C-T None NT UV No
6 256 tCCAc C-T Trp-Stop NT UV/PUVA
6 293 gGACc C-T None T UV
10 481 cCACt C-T Val-Met NT UV
IVS2+10 — ccgccc C-T — — UV
21 1,163 cGCCg C-T Gly-Asp NT UV
C1 Yes 2 72 tGGCc G-T Gly-Ser NT PUVA No
2 83 gTTTc T-C Phe-Leu T PUVA
IVS10+61 — Ggcca C-T — — UV
11 514 cATCa C-T Asp-Asn NT UV/PUVA
E1 No No
E3 No Yes
BCC, basal cell carcinoma; PTCH, patched; PUVA, psoralen plus UVA.
1These p53 data were previously reported (Seidl et al., 2001).
2These tumor data were previously reported (Seidl et al., 2001). No material from tumors A4, D1, E2, E4, and E5 was available for this study, having been
completely used up in the previous study by Seidl et al. (2001).
3The sequence for the strand (transcribed or nontranscribed) containing a pyrimidine at the mutation site is shown in the 50-30 direction. Nucleotides of the
affected codon are shown in capital letters. Mutated bases are shown in bold letters. Multi- and dipyrimidines bearing the UV fingerprint are underlined
once; potential psoralen-binding sites (i.e., 50TpG/50CpA and 50TpT/5ApA) containing mutations are underlined twice.
4T, transcribed strand containing an affected pyrimidine; NT, nontranscribed strand containing an affected pyrimidine.
5UV, UV fingerprint (C-T transition at dipyrimidine); PUVA fingerprint, mutation arising at potential psoralen-binding site (see footnote 3).
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combinations) (data not shown), which
all had been previously described
(Heitzer et al., 2007).
We compared the mutational
status of both PTCH and p53. Three
tumors (A1, A2, and A3) bore mutations
in both genes; two tumors (B2 and C1),
only in PTCH; one tumor (E3), only in
p53; and two tumors (B1 and E1), in
neither gene (Table 1). We also com-
pared the PTCH mutation spectra of
our sample of PUVA-associated BCCs
versus sporadic (presumably non-PUVA
treated) BCCs from the general popula-
tion. We found no significant difference
between them (Fisher exact test,
P40.05) (Figure 1). Interestingly, the
UV fingerprint predominated in both
sets of BCCs.
The prevalence of PTCH and p53
gene mutations in BCCs in this study
(63 and 46%, respectively) is consistent
with that reported by Zhang et al.
(2001) in early-onset BCCs from the
general population (54% (13/24) and
46% (11/24), respectively). Our muta-
tional analyses are consistent with
previous mutational analyses of other
tumor suppressor genes and oncogenes
in PUVA-associated skin cancers and
precursor lesions, including p53 in
BCC (Seidl et al., 2001) and p53,
Ha-ras, and INK4a-ARF in squamous
cell carcinoma or PUVA keratoses
(Nataraj et al., 1997; Wang et al.,
1997; Kreimer-Erlacher et al., 2001,
2003; Seidl et al., 2001; Stern et al.,
2002; Wolf et al., 2004b). In all those
studies, UV fingerprints and 50TpG
mutations dominated the mutation
spectra, whereas 50TpA mutations (that
is, the most typical psoralen photoad-
ducts and PUVA-induced mutations in
cell culture (Monti et al., 2000) and
animal studies (Nataraj et al., 1996))
were comparatively rare. This predomi-
nance of UV fingerprint mutations may
have been due to UVB and/or natural
sunlight exposure, which is known to
benefit psoriatic skin lesions (Seidl
et al., 2001). Indeed, all patients with
PUVA-associated BCCs in this study
also had a history of UVB therapy (Seidl
et al., 2001). However, the prominence
of 50TpG mutations particularly in squa-
mous cell carcinoma is also consistent
with the results of a laboratory study
(Gunther et al., 1995) in which a third of
all mutations induced in supF-contain-
ing murine fibroblasts by low (but
clinically relevant) PUVA doses oc-
curred at 50TpG sequences. Conversely,
the similar frequency of 50TpG muta-
tions in both PUVA-associated and
non-PUVA-associated BCCs (Figure 1)
suggests that those mutations might
have been caused by agents (yet un-
identified) other than PUVA.
Together, our results argue—at least
in the case of PUVA-associated BCCs—
against the controversial theory that
multiple BCCs arising in a single
individual are monoclonal in origin
(Walsh et al., 1998; Saldanha et al.,
2002; Shulman et al., 2006; van Steen-
sel and Frank, 2006). For example,
Shulman et al. (2006) inferred from loss
of heterozygosity analyses and X-chro-
mosome inactivation studies of multiple
BCCs from single patients that most of
the lesions originated from a single
tumor cell clone, independent of the
anatomical site and time of occurrence.
Our analysis of the PTCH mutations
in two individuals with multiple
BCCs suggests otherwise (Table 1).
Three lesions from one individual
(A1–A3) bore distinctly different PTCH
mutations. Two lesions from another
individual differed in that one bore no
PTCHmutations (B1) and the other bore
three diverse mutations (B2), nor did
our previous p53 sequencing analyses
(Seidl et al., 2001) give any indication
of BCC monoclonality, as evidenced
by a diversity of p53 mutations in four
lesions from patient A and in five
lesions from patient E. As others have
already noted (van Steensel and Frank,
2006), this in turn suggests that DNA
sequencing analysis of BCCs from
the general population (like that of
PUVA-associated BCCs reported here)
might help resolve the controversy
surrounding monoclonality.
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patients. PUVA-associated BCCs (n¼ 5) and sporadic (presumably non-PUVA-associated) BCCs (n¼ 29)
obtained for a previous study in our laboratory (Heitzer et al., 2007) were compared in terms of their
PTCH mutation spectra (i.e., the type and frequency of missense/nonsense, silent exonic, and intronic
PTCH mutations). A total of 19 mutations were detected in the PUVA-associated BCCs; a total of 51
mutations, in the sporadic BCCs. In both groups, a number of C-T and CC-TT transitions were
detected opposite a potential psoralen-binding site (i.e., a 50TpG sequence) (see also Table 1). Because of
their ambiguous origins (UV versus PUVA fingerprint), these mutations were plotted in separate columns.
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SERPINE1 (PAI-1) Is a Prominent Member of the Early
G0-G1 Transition ‘‘Wound Repair’’ Transcriptome in p53
Mutant Human Keratinocytes
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TO THE EDITOR
Serum-stimulation of quiescent (G0)
keratinocytes initiates a temporally
regulated program of transcriptional
activity required for G0/G1 transit and
subsequent entry into the proliferative
cycle (Qi and Higgins, 2003). Expres-
sion profiling of such ‘‘activated’’ kera-
tinocytes identified physiologically
relevant subsets of cell cycle/growth
state-regulated genes (Gromov et al.,
2002; Gazel et al., 2003). Indeed, non-
cycling human (HaCaT) keratinocytes
express a differentiated (i.e., super-Abbreviation: FBS, fetal bovine serum
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The Early G0-G1 Transition ‘‘Wound Repair’’ Transcriptome
